Compare FULC & BZAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | BZAI |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 281.1M | 268.9M |
| IPO Year | 2019 | 2021 |
| Metric | FULC | BZAI |
|---|---|---|
| Price | $3.69 | $0.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $3.67 | $1.75 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 11-12-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.43 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9.24 |
| Revenue Next Year | N/A | $168.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $0.12 |
| 52 Week High | $15.74 | $2.82 |
| Indicator | FULC | BZAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 24.32 |
| Support Level | $3.62 | N/A |
| Resistance Level | $3.81 | $0.23 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 7.69 | 1.28 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Blaize Holdings Inc provides transformative artificial intelligence (AI)-enabled edge computing solutions comprised of both its proprietary hardware and software, and third-party hardware solutions. Its portfolio includes programmable AI processors in various form factors, which can be deployed across sectors such as smart cities, defense, retail, and enterprise markets. The company operates as a single operating and reportable segment. The majority of the company's revenue is derived from Hardware revenue, which includes the sale of its semiconductor products and/or third-party hardware products that support semiconductor products through various supply agreements. Geographically, it generates the maximum revenue from China.